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ABSTRACT

Anti-depressive and Anti-obesity Changes Following Either Dietary Isoflavone Treatment or
Injection Treatment with the Isoflavonoid Equol: Positive Response Dependent on
Animal Age and Ovarian Status in Female Long-Evans Rats

Crystal Blake
Department of Physiology and Developmental Biology
Doctor of Philosophy

Two conditions associated with ovarian depletion are increased potential for depressive
episodes and increased abdominal weight gain. In five different experiments we examined the
effect of soy-containing diets or equol injections on depression, serotonin levels, weight gain
(BW) and white adipose tissue (WAT) deposition of female Long-Evans rats in various stages of
life. Rats were intact, ovariectomized or experienced natural ovarian failure (NOF). While this
paper will present each experiment, only experiment 5 is outlined here due to space limitations.
From conception the rats were exposed to either a soy-rich (Phyto-600) or low-soy diet (Phytolow). Animals experienced NOF at approximately 300 days. At 330 days-old animals underwent
the Porsolt forced swim test (PFST). One month later (following 1 week of equol injections in
Phyto-low fed animals) the animals were again tested in the PFST. Serum was collected before
the first PFST and following the second PFST for serotonin and isoflavone analysis. This
experiment demonstrated that animals fed a soy-rich diet have decreased BW and WAT
compared to a low-soy diet. At the first PFST, the Phyto-low fed NOF females displayed
increased immobility and lower serotonin levels compared to the Phyto-600 NOF females
indicating the Phyto-low animals were more depressed than the Phyto-600 females. The second
PFST demonstrated equol injection significantly increased both time mobile and serum serotonin
levels in the Phyto-low fed rats suggesting that equol has antidepressant effects. This experiment
demonstrated that isoflavone exposure has antiobesity-like effects. Furthermore, isoflavones
(particularly equol) appear to have antidepressant potential in NOF females.

Keywords: Rat, isoflavones, behavior, depression, ovarian failure, body weight
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A. Introduction:
Menopause
Menopause is strictly defined as the permanent cessation of menstrual periods due to the
loss of ovarian follicle activity accompanied by the termination of ovarian steroid production and
availability (1-5). Females are born with a finite number of ovarian follicles, which determine
their reproductive lifespan; follicular depletion results in ovarian failure (termed menopause in
humans) (5-7). Ovarian failure can occur as a result of natural ovarian depletion with normal
aging, be chemically induced, or surgically instigated by bilateral removal of both ovaries (4,7).
Natural menopause (menopause as a result of aging) is preceded by irregular cycles first
displayed between 30 to 40 years of age in humans followed by a rapid decline of fertility during
the fourth decade of female life (8). This period, referred to as perimenopause, is usually
associated with a gradual decline in sex hormone production over the course of several years
(3,5). In the United States, menopause generally occurs between 45 and 65 years of age with an
average age of 51 years (9). This age has not significantly changed over time or between ethnic
groups (10). However, menopause can occur much earlier if a woman is exposed to any
chemical or substance that decreases her ovarian follicle reserve (7). Early or premature
menopause can be chemically induced or surgically initiated (5). Menopause is considered to be
premature if it occurs before a woman is 40 years-old and early if it occurs at or before she is 45
years-old (11).
Cancer treatments such as radiation therapy or chemotherapy can chemically induce
premature or early menopause (7,12). Radiation therapy can cause direct damage to the ovaries,
which can result in ovarian failure (12,13). Chemotherapy influences both ovarian follicle
depletion and general organ toxicity (14). Women who undergo either radiation therapy or
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chemotherapy are more likely to enter menopause at a younger age (7,13,15). Ovarian depletion
by either method depends on the age of the patient, the type of agents used and dose, and the
length of exposure (7,16). Although these cancer therapies are the best known, any substance or
treatment that decreases the number of primordial follicles can also induce premature or early
ovarian failure (7).
Bilateral oophorectomy is the most abrupt form of early or premature menopause. Each
year in the United States one quarter of a million women undergo surgical menopause (bilateral
oophorectomy) (17). This procedure is accompanied by a drastic and abrupt decrease in
circulating estrogen and progesterone levels due to the loss of the ovaries (5).
Regardless of the cause, menopause (premature, early, or natural) brings changes that
affect female health and quality of life. The postmenopausal period is associated with increased
risk for certain diseases and conditions such as cardiovascular disease, osteoporosis, and
neurological disorders (18-29). These risks are further increased when menopause is premature
or early (30,31). For example, surgically induced menopause before age 45 increases the risk for
premature death and neurological problems such as dementia (5,25).
Symptoms
Menopause is associated with certain transitional symptoms, which often result in the
patient seeking medical assistance. Some of the more common symptoms addressed here
include hot flashes, weight gain, and depression.
Hot flashes are the most recognized symptom of menopause and a common reason
women seek medical attention (32). Hot flashes occur in 75-85% of postmenopausal women
and 30% of these women describe these hot flashes as severe (33-35). Hot flashes are associated
with estrogen withdrawal; however, studies have shown no significant differences in serum
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estrogen levels between women who experience hot flashes and women who do not (36). While
other hormones have been associated with reduction of hot flashes, the exact causes are unknown
(34).
Menopause is also associated with increased body weight, body mass index (BMI), and
fat content (37-39). Estrogens are known to affect energy intake, fat accumulation, distribution,
and breakdown (lipolysis), and locomotive activity (energy expenditure) (40-43).
Postmenopausal weight gain is usually centrally or abdominally located and associated with low
estrogen levels (38,44). Unfortunately, menopausal weight gain is also associated with increased
risk for both breast cancer and cardiovascular disease, causing it to be more than just an agerelated inconvenience (39,45).
Finally, depression is one of the major debilitating symptoms of menopause (46). In
general, depression is a disorder more commonly found in women than in men. This difference
is associated with the differing estrogen levels (47). For example, the risk for depression
increases during perimenopause, a time when estrogen levels are decreasing (48,49). Moreover,
estrogens are known to be involved in regulating the expression and effects of behavioral
hormones such as serotonin (50).
Serotonin is a chemical messenger present in the gastrointestinal tract, the blood, and
other various organs (51). However, serotonin’s best-known effects are in the nervous system
where it functions as a behavioral neurotransmitter associated with affective disorders (51).
Decreased serotonin concentrations are associated with increased depression, anxiety, and other
affective disorders (52,53). Because estrogens normally affect serotonin concentrations,
receptors, and function, the lack of estrogen would also have effects (50).
Hormone Replacement Therapy
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Hormone replacement therapy (HRT) is the gold standard treatment for menopausal
symptoms and currently is the only treatment approved by the FDA (54). Until the 2002
Women’s Health Initiative (WHI), HRT consisted of either estrogen only for women without a
uterus (0.625 mg/day conjugated equine estrogen) or estrogen plus progesterone for women with
a uterus (0.625 mg/day conjugated equine estrogen plus 2.5 mg/day medroxyprogesterone
acetate) (55). Prior to 2002, it was thought that HRT could potentially decrease the risks for
cardiovascular disease, osteoporosis, and dementia (33). However, the 2002 WHI results raised
questions about whether HRT should be given as a preventative treatment (19). Furthermore, the
2002 WHI raised concerns with the current HRT treatments due to the increased risk for breast
cancer, heart attack, stroke, and endometrial cancer (19,26). As a result, researchers, doctors,
and postmenopausal women began looking for alternative treatments to HRT for their
menopausal symptoms (54,56).
However, HRT is important in women who enter menopause early or prematurely.
Professional organizations such as the North American Menopause Society, The International
Menopause society, and the British Menopause Society recommend the use of HRT in women
who undergo premature menopause (57-59). HRT protects these women from premature
coronary heart disease and death, prevents bone loss, lowers risk of fracture, reduces risk of
neurological impairment, and effectively treats the climacteric symptoms of menopause (30,54).
Estrogen Receptors
The estrogen receptors are part of a family of steroid nuclear receptors (60). Steroid
receptors are intracellular transcription factors, which regulate the transcription of certain genes.
When ligand is present these receptors dimerize and bind to their respective hormone response
elements on the DNA (60,61).

Steroid receptors have several structural components in
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common and two of these structures are the DNA binding domain and the ligand binding domain
(60).
The first estrogen receptor, estrogen receptor alpha (ERα), was discovered in the 1950s
and cloned in 1986 (62). The second estrogen receptor, estrogen receptor beta (ERβ), was
discovered and cloned in 1996 (63). While the DNA binding domains for the estrogen receptors,
alpha and beta, have a 96% homology, their ligand binding domains have only a 53% homology
(64). This difference in the ligand binding domain indicates that there can be variation in
chemical binding affinity between ERα and ERβ (64).
ERα is commonly known as the proliferative receptor and the receptor usually blamed in
estrogen responsive breast cancer (65,66). On the other hand, ERβ appears to exhibit an
inhibitory effect on ERα-mediated gene action though this is not ERβ’s only function (67).
Furthermore, it appears that the concentration and ratio of these receptors in various tissues
determines the relationship between the two receptors (66,68-71).
The discovery of a second estrogen receptor changed the understanding of how estrogens
work in the body and treatment possibilities. For example, these two receptors, though they are
widely distributed throughout the body, do not have identical distribution. ERα is found
primarily in the uterus, liver, kidney and heart. ERβ is found in the ovary, prostate, lung, GI tract,
bladder, central nervous system, and bone marrow. Both receptors are co-expressed in tissues
such as the mammary gland, the epididymis, thyroid, adrenal gland, bone, and certain parts of the
brain (72,73).
Due to the different distributions and actions of the estrogen receptors, specialized
treatments can now be aimed specifically at either of the two receptors. 17β-estradiol, the most
potent naturally occurring estrogen binds to both estrogen receptors with equal affinity (74).
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Other chemicals, however, can selectively bind one or the other. Selective estrogen receptor
modulators (SERMs) are biochemical compounds able to agonize or antagonize estrogen
receptors (75). SERMS bind the estrogen receptors with differing affinities with some
compounds binding preferentially to either ERα or ERβ (74). Furthermore, the physical effects
of these compounds can vary between organs of the same body (75,76).
Two of the best known SERMs are tamoxifen and raloxifene. Tamoxifen is used as a
breast cancer treatment because it has antiestrogen activity in the breast (76,77). Tamoxifen has
equal affinity for both estrogen receptors, reduces the risk of cancer, increases bone density, and
lowers circulating cholesterol (66,78). However, tamoxifen has potential problems because it
acts as an ER agonist in the uterus. As a result, tamoxifen increases both endometrial thickness
and risk for endometrial cancer (66). Raloxifene is a SERM aimed at decreasing bone loss and
preventing osteoporosis (76,77,79). It has a similar chemopreventive profile to tamoxifen
including potential as a breast cancer treatment; however raloxifene has fewer undesirable sideeffects (66,77). Unfortunately, recent studies have shown that these side-effects include
increased vasomotor symptoms, increased risk for venous thromboembolic events, and increased
risk of fatal stroke (79).
Alternative Treatments
As mentioned before, over 75% of postmenopausal women experience menopausal
symptoms (33). However, since the 2002 WHI only 10-25% will seek help from traditional
means (80). Since 2002 more women have been turning away from traditional hormone
replacement therapy (exogenous estrogens) and seeking alternative and complementary sources
for relief from menopausal symptoms (56,80,81). Many women appear to prefer these alternative
supplements because they feel these treatments better fit their personal lifestyles, values, and
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beliefs (80,82). Even women who do use traditional treatment will often also take botanical
supplements without their doctor knowing (80). Some common botanical supplements include
black cohosh, red clover, soy isoflavones, dong quai, ginseng etc.
Black cohosh is a perennial plant native to North America that has been used by
American Indians for gynecological conditions since before European arrival in the Americas
(83). Estrogenic activity has been suggested but not demonstrated, and existing data imply black
cohosh uses serotonin pathways rather than estrogenic pathways (84,87-89). Currently, this
botanical demonstrates effective treatment of menopausal symptoms and could be used safely for
six months. However, no long-term studies have been performed (80).
Red clover is a plant native to Europe and western Asia, which contains high levels of
isoflavones similar to soy. However, soy contains higher levels of daidzein and genistein while
red clover has higher levels of formononetin and biochanin A. Studies involving this compound
demonstrate no ease of menopausal symptoms in spite of the similarity to soy (80).
Dong quai is an herb native to eastern Asia and China (83). It has been used for more
than 1000 years as a spice, tonic and medicine and is the most prescribed Chinese herbal
medicine for female problems (80,83). However, there is very little data currently available on
the efficacy of this compound in treating menopausal symptoms (80). What is available suggests
that dong quai alone does not relieve menopausal symptoms (90).
Ginseng is another Asian herb popular in the American market (90). While this drug
seems to help with mood and sleep, it does not appear to treat vasomotor symptoms (90).
Furthermore, ginseng has not demonstrated any estrogenic effects (80). Similarly, other
botanicals such as valerian, ginkgo biloba, St. Johns’ wort, and motherwort are used for
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treatment of depression and mood symptoms and do not appear to have effects on vasomotor
symptoms (80).
Use of soy isoflavones became prominent following observations that Asian women
living on the isoflavone-rich Asian diet express few menopausal complaints. Whether or not this
difference is due to diet, culture, or both is yet to be determined (80). Soy isoflavones will be
discussed in greater detail in the phytoestrogen section. The most common isoflavones are
daidzein, genistein, biochanin A, and formononetin (80).
A frequent assumption made by many women is that botanicals are safe to use because
they are “natural” (80,91). However, the efficacy of these alternative medicines as viable
menopausal symptom treatments are still a focus of scientific research (80,90). Currently no
consensus on dosing, length of exposure or efficacy for these compounds exists (92). Longterm, randomized, placebo-controlled studies on the effects of alternative and complementary
medicine in postmenopausal women have yet to be performed (80).
Polyphenols
Polyphenols are a plant-derived group of chemical substances found in berries, grapes,
walnuts, peanuts, pomegranates, and other fruits and vegetables (93). Polyphenol extracts and
preparations are commonly available as dietary supplements (94). The largest and best studied
polyphenols are the dietary estrogen-like molecules called phytoestrogens (93).
Phytoestrogens
Phytoestrogens are non-steroidal plant-produced compounds with structural and
functional similarity to 17β-estradiol (95). Phytoestrogens are able to bind the estrogen receptors
however; many phytoestrogens preferentially bind ERβ (96). Phytoestrogens are divided into
three categories: lignans (found in flaxseed in large quantities), coumestans (derived from
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sprouting plants like alfalfa), and isoflavones (derived principally from soybeans) (66). Soy
isoflavones are the most abundant phytoestrogen that occur in both rodent and human diets and
the most studied (96). The most abundant concentrations of isoflavones are found in legumes and
soybeans (97).
Soy isoflavone diets appear to have beneficial effects on health. Asians, who consume
large daily amounts of soy isoflavones (20-50mg/day vs. 0.5-1.0mg/day in Western diets), tend
to have lower rates of hormone-dependent cancers, obesity, and coronary heart disease (97,98).
Like many other phytoestrogens, isoflavones can act as SERMs and have an affinity for both
estrogen receptors; however, in general, isoflavones have a higher affinity for ERβ (96). The
major soy isoflavones include daidzein and genistein (74,96). Rising to specific prominence has
been the isoflavonoid equol, daidzein’s intestinally produced metabolite. Equol has a much
higher affinity than daidzein for estrogen receptor beta and a similar binding affinity to genistein
(74).
Figure A

Because soy isoflavones can bind to the estrogen receptors, phytoestrogens could be a
helpful alternative to HRT in treating some of the symptoms of menopause such as depression,
weight gain, and vasomotor symptoms. This study will focus primarily on phytoestrogens’
(particularly equol’s) effects on behavior and weight gain in two animal models of menopause
(ovariectomy and natural ovarian failure).
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B. Materials and Methods:
General Methodology
This study reports the results of five different experiments designed to investigate the
effects of isoflavone(s), administered in the diet or by injection, in female, Long-Evans rats.
Animals were of varying ages and were gonadally intact, ovariectomized, or experienced natural
ovarian failure (NOF).

The parameters examined in this study included animal behavioral

analysis, animal body weight gain, white adipose tissue deposition, and serum concentrations of
serotonin and phytoestrogen isoflavones. Also compared in this study was the effectiveness of
treatment timing, length, and mode of administration.
Animals and Housing
All animals tested in these experiments were female, Long-Evans rats. An in-house
breeding protocol was used to generate the female offspring used in experiments 1, 2, 4, and 5.
The animals used in this breeding protocol, as well as the ovariectomized females used in
experiment 3 (ovariectomized at 40-45 days-old), were purchased from Charles River
Laboratories (Wilmington, MA, USA), then shipped to our animal facility at approximately 5055 days-old. Once at our facility the animals were placed on a 12-hour light/dark cycle (6am6pm) with a light intensity of approximately 80 foot candles and were allowed free access to
both food [diet treatment(s)] and tap water. All animals were housed in clear plastic cages with
wire lids. Cage dimensions were 20 cm high, 24 cm wide and 40 cm long. The animals in
experiment 3 and young adult animals used for breeding were housed in individual cages. The
female rats tested in experiments 1, 2, 4, and 5 were initially housed with their mothers from
birth until weaning at 21 days. From 21-40 days the animals were housed in groups of 3 to 4 rats
per cage. From day 40 to day 60 these animals lived in paired housing and from day 60 to the
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end of each experiment the females were housed in individual cages. All animals obtained from
the supplier (Charles Rivers) were given at least one month to adapt to the new surroundings and
diet treatments before either being mated or beginning treatment.
Mating
As stated above, the male and female animals used to produce the animals in experiments
1, 2, 4, and 5 were purchased from Charles River Laboratories when 50-55 days-old. Breeding
the animals at our facilities allowed control over the animal’s exposure to their individual and
respective diets. The male and female animals were bred at approximately 90 days-old. Mating
took place in suspended wire cages. Removable cardboard sheets were placed beneath the cages
to catch feces and vaginal plugs. Each female rat was housed with a male until inseminated at
which point she was exchanged for another female. Insemination was noted by the presence of
vaginal plugs on the cardboard and these sheets were checked twice a day (8-9 am or 4-6 pm).
All the males were fertile and each male inseminated between two and four females. One female
fed the Phyto-600 diet and two females fed the Phyto-low diet did not get pregnant in the course
of these experiments.
Diets
The animals obtained from Charles River laboratories were exposed prior to their arrival
at our facility, to a diet (standard chow) containing approximately 200 ppm isoflavones (as
previously determined by our laboratory) (99). These animals were allowed one month on their
new diets (see below) before mating, treatment or testing occurred in order to decrease possible
interference by previous exposure to dietary isoflavones. Once at our facility the animals were
exposed to one of two diets: the Phyto-600 or the Phyto-low diets. The Phyto-600 diet is a
phytoestrogen rich diet containing roughly 600 ppm soy isoflavones (Harlan Teklad Rodent Diet
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8604, Madison, WI, USA). The Phyto-low diet is poor in phytoestrogen content with between
10-15 ppm soy isoflavones (Zeigler Bros., Gardner PA, USA) [catalog# 541200-12-00, Rodent
PHY RDC]. All diet isoflavone concentrations were determined by our laboratory using gas
chromatography and mass spectrometry (GC/MS) (99,100). The diets were balanced and
matched for equal percentages of protein, carbohydrate, fat, vitamins and minerals (99).
Injections
All animals in experiments 1, 2, 4, and 5 received subcutaneous injections of either a
placebo or 5.0 mg/kg body weight equol. The females on the Phyto-600 diet received placebo
injections of dimethyl sulfoxide (DMSO). DMSO acts as an absorptive agent, increasing the
penetration of equol through the tissues and into the circulation. It does not appear to have
detrimental effects on the animals and is in fact employed for medical treatments in humans
(101). The animals on the Phyto-low diet were injected with 5.0 mg/kg body weight of the soy
isoflavonoid equol (in DMSO) (LC Laboratories, Woburn, MA, USA). All injection volumes
were 0.1 cc and administered subcutaneously at the nape of the animal’s neck. The rats were
wrapped carefully in cloth to decrease animal stress and the females were returned to their cages
directly following injection. All injection schedules varied among the experiments. Each
schedule is listed below in the experiment protocols.
Age and Ovarian Status
The females tested in each experiment were of various ages and ovarian status. This
allowed us to compare treatment effects at each of these ages and conditions. The females
investigated in experiment 1 were gonadally intact. Animal testing and treatment occurred from
120 to 210 days-old. Experiment 2 animals were also intact, however, diet treatment began at
conception and further treatment and testing occurred between 115-145 days-old. The animals
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examined in the third experiment were ovariectomized at 50-55 days-old. Treatment and testing
occurred from 85-100 days. The females in experiment 4 began diet treatment at conception.
These animals were ovariectomized at approximately 100 days. Testing and further treatment
occurred between 150-222 days-old. The females in the fifth experiment also began dietary
treatment at conception, which continued life-long until the end of the study. Testing and further
treatment began at 295 days-old and continued until 365 days-old.
Sexual Age of Animals
The Long-Evans female rat enters puberty when approximately 40 days-old (102). This
particular breed of rat experiences decreased reproductive ability beginning at five months and
natural ovarian failure (NOF) occurs approximately between 280 to 290 days of age (103). The
timing of NOF was confirmed in experiment 5 by this lab using histological examination of
vaginal epithelial cells when the females were between 295-305 days-old. In contrast, the
average human female begins puberty when approximately 12 years old (104). In the U.S. the
average age of menopause or human ovarian failure is approximately 51 years (105,106). By
using these ranges in fertility between these two species, associations between human and rat
ages were roughly approximated to better estimate possible responses in humans. Theoretical
estimations of human responses to similar conditions were then made. The table below displays
the sexual timing, ages, and the approximate rat/human age comparisons.
Sexual Timing

Rat (days

Human (years)

Puberty

35-40

12-13

Young Adulthood

120

20-24

Mid-age

200

35-40

Post Ovarian Failure

300-360

50-55
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Ovariectomy
Only the animals in experiment 4 were ovariectomized while at our facility. All animal
surgeries were performed under the direction of the university veterinarian. Anesthesia (a 3 cc
buprenex, 2 cc domitor, and 5 cc ketamine mixture) was administered intraperitoneally at
0.05cc/100g animal body weight. Anesthesia depth was measured using the toe pinch reflex.
Animal body temperature was maintained with a warm water blanket during surgery and a
heating pad following surgery. A single abdominal incision was made in each female and the
ovaries removed. The incisions were closed with sterile surgical staples. Following surgery the
animals were placed on a heating pad, injected with 0.1 cc of atipamezole, a reversal drug, and
allowed to regain consciousness. Approximately 6 minutes were required to completely
anesthetize animals. Once anesthetized, a reversal drug was administered and animals regained
consciousness after about 10 minutes. Post-treatment painkiller was administered via drinking
water for 4-5 days after surgery (20 ml acetaminophen pediatric elixir (32mg/ml) per 500 ml tap
water). The animals were carefully watched for signs of infection or illness. All of the females
in experiment 4 were allowed seven weeks to recover from ovariectomy before any other
treatment occurred.
Porsolt Forced Swim Test
The Porsolt Forced Swim Test (PFST) is the standard antidepressant test used in both
academic and pharmaceutical laboratories world wide to screen new drugs or compounds with
potential for antidepressant activity (107,108). This test examines behavioral despair expressed
in rodents following antidepressant treatment. Animal behavioral despair is expressed through
animal immobility. Depressed animals assume a state and position where only very simple
movements are required to keep the nose above water (i.e., floating). The PFST examines the
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length of time the animal struggles when exposed to a novel environment from which it cannot
escape and measures the length of time the animal spends immobile (107,109). Other parameters
that can be examined by this test include swimming distance, speed, escape behaviors etc.
Animals that demonstrate greater mobility, faster speed, and longer swimming distance are
considered to be less depressed. These animals also tend to display more escape behaviors such
as diving or inversion (positioning the head/body below the waterline, but not diving) while
searching for an exit. The PFST uses a cylindrical container (diameter 19 cm, height 43 cm)
which is filled to a water depth of 35.6 cm. This depth makes it difficult for animals to touch or
rest their tails on the bottom of the container as well as preventing escape out of the top of the
container (110). Test duration was 8 minutes. Animal behavior was recorded by a video camera
located above the containers and each animal’s movements were measured and analyzed using
Anymaze® computer software (Stoelting Co., Wood Dale, IL, USA). Parameters examined by
Anymaze® include swimming speed, total swim distance, and time spent either mobile or
immobile. Escape behaviors were also observed and recorded by a trained observer who sat
outside the room and manually recorded the number of times the animals either dove or inverted
themselves. This observer also recorded the number of fecal boli released by each animal during
the test as this is seen as an emotional response.
While the PFST is the standard antidepressant screening test there are other tests
designed to measure affective disorders displayed in animals (111). These tests are designed to
analyze depressive-related or anxiety-related behaviors. One of the tests, which also examine
animal depressive-related behaviors by testing for immobility, is the tail suspension test first
used in 1985. In this test the rat is suspended by its tail for approximately six minutes and the
time the animal spends immobile is measured (112).
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Anxiety-related behaviors are related to and often concurrent with depression. Some of
the tests designed to examine animal anxiety include the elevated plus maze, the light/dark box,
the open field test and the fear conditioning-freeze monitoring test. In the elevated plus maze,
the animal is placed on a raised plus-shaped platform. Two arms of the platform are surrounded
by high walls while the other two have none. The test measures the time the animal spends in
the open arms of the maze compared to the closed (walled) arms. The less anxious animal will
spend more time on the open arms (111,113). In the light/dark box test the animal is placed in a
container with two divisions. One division is enclosed and dark while the other is clear and
light. The amount of time the animal spends in the clear side is recorded. Animals expressing
lower anxiety-related behaviors will spend less time in the dark side of the box (111). The open
field test examines exploratory behaviors in the rat. The rat is placed in the center of a large
open box and the time spent exploring the area and away from the walls of the apparatus is
measured. Less anxious animals will explore more (111). Finally, the fear conditioning-freeze
monitoring test is designed to gauge an animal’s response to anxiety inducing stimuli. The
animal is placed in a container capable of releasing one of three stimuli: sound, light, or electric
shock. Animal movement is tracked and animals that are less anxious will recover from the
stimuli faster and spend more time mobile (111).
Body Weight (BW), White Adipose Tissue (WAT) Deposition and Blood Collection
Animal body weights were recorded at different intervals mentioned specifically in each
experiment. All animals were weighed using a Mettler 1200 balance (weight recorded in grams
+ 0.1 grams) (St. Louis, MO, USA). Once injection treatments began all body weight
measurements were recorded prior to the subsequent injections. Following animal sacrifice,
abdominal white adipose (WAT) tissue was dissected from the base of the pelvic cavity to just
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below the diaphragm and weighed on a Sartorious balance (weight recorded in milligrams + 1.0
mg) (Brinkman Inst. Co., Westbury, NY, USA). Trunk blood was also collected and centrifuged
at 2400 X g. Serum was then collected and stored at -20ºC until it was assayed for serotonin and
isoflavone levels.
Serotonin ELISA
Serum serotonin concentrations were measured using ELISA kits (cat#IB89527-12-1610)
obtained from Immuno Biological Laboratories (Minneapolis, MN, USA). Only experiment 3
serum was not assayed for serotonin levels due to a lack of sufficient serum volume.
Serotonin is known to be present in and affect a number of both individual organs and
organ systems in the body. Most of the body’s serotonin is located in various organs or blood
components or regions outside of the nervous system. However, serotonin’s better known
effects are in the brain due to serotonin’s involvement in influencing behavior (51). Decreased
serotonin concentrations are associated with depression, anxiety, and other affective disorders
(52). Peripheral serotonin levels appear to correlate with CNS concentrations and therefore
could correlate with behavioral states (53,114-116).
Serotonin concentrations and function can be affected by estrogens, which indicate
potential for other estrogen-like chemicals to affect serotonin levels and function (50).
Phytoestrogens, which are able to bind estrogen receptors, could have similar effects on
serotonin levels and function. Because phytoestrogens’ ER binding affinities are much lower
than natural 17β-estradiol these effects while similar would be less (74,96,117).
Serum Phytoestrogen Levels
Gas chromatography/mass spectrometry (GS/MS) was used to determine serum
isoflavone concentrations for all samples collected as previously reported by our laboratory (99).
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Specific circulating isoflavone concentrations were determined for genistein, daidzein, and the
isoflavonoid equol using internal control standards as previously reported (99,118). The specific
protocol for this technique was reported in greater detail in papers published by Axelson et al.
and Setchell et al., in 1982 and 1997 respectively (119,120).
Treatments
Experiment 1: The objective of this experiment was to examine the effect of either diet
and/or isoflavone injection on the study parameters (BW, WAT, behavior, etc.) in young adult,
female rats. Half the animals in this experiment underwent a diet change during young adulthood
after being exposed from conception to a phytoestrogen-low diet. The remaining animals
continued on the phytoestrogen-low diet and received supplemental injections later in adulthood.
Figure B

Twenty-three weight-matched, intact, female, Long-Evans rats were used in this
experiment representing at least six litters. These animals were conceived on the Phyto-low diet
and remained on this diet until 120 days-old. This age roughly corresponds to early twenties in
human years. When the animals were 120 days-old, animals were weight-matched and twelve
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rats (or approximately ½ of the total number of animals) were switched to the Phyto-600 diet.
Animal body weight was measured and recorded three times a week during the course of the
study.
The Porsolt Forced Swim Test (PFST) was performed at three different points during this
experiment: 120 days, 150 days, and 200 days. The first PFST was administered to record
baseline animal behavior prior to the diet change. The second PFST, administered at 150 days,
examined changes in the expression of depressive-related behaviors as a result of the diet
change. The third PFST examined the effects of equol administration on depressive-related
animal behaviors in the Phyto-low fed animals. The parameters recorded for each test are as
mentioned above (mobility, total swim distance, average swim speed, escape behaviors, etc.).
Prior to the final PFST, the females received daily injections of either equol or DMSO (days
194-200). The animals on the Phyto-low diet received injections of 5 mg/kg (body weight) equol
in DMSO and the Phyto-600 fed animals received vehicle-DMSO injections. Injections
continued until the end of the experiment.
Animals were killed via decapitation at 210 days. Animal body weight, white adipose
tissue weight and trunk blood were collected. Serum was tested for serotonin and isoflavone
concentrations.
This experiment examines two separate situations in healthy, sexually intact adult
females. In both scenarios the animals were meant to model humans raised on an isoflavone
poor (Western) diet but have the ability to produce equol from daidzein if soy foods were
consumed. In general, only 30-50% of the human population is able to produce equol from
daidzein (121). The first part of this experiment examined dietary effects on behavior, body
weight, and adipose tissue deposition in gonadally intact female rats exposed from birth to an
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isoflavone poor (Western) diet. During young adulthood these female rats were switched to an
isoflavone rich diet which they continued to eat until almost mid-age, which is approximately 35
years and older in humans. The second part of this experiment examined the effects on study
parameters in gonadally intact female rats that remain life-long on the isoflavone poor diet and
recieve equol during mid-age to model potential benefits of equol supplementation.
This experiment addressed three main questions. The first, is there a difference in study
parameters based on diet in intact females? Next, do phytoestrogens have visible effects in the
presence of naturally occurring estrogens? Last, does route of administration (diet versus equol
injections or supplementation) have an effect on study parameters?
Experiment 2: This experiment examined the beneficial effects of lifelong phytoestrogenrich diet exposure in intact, female rats on the study parameters (behavior, BW, WAT, etc) in
early young adulthood. Approximately half of the females in this experiment were exposed
lifelong to a phytoestrogen rich diet. The remaining females were exposed lifelong to diet poor
in phytoestrogen content; these females received injections of equol supplement during early
young adulthood.
Figure C
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Eight females were selected from 4 litters of Phyto-low fed pups while seven females
were chosen from 3 litters of Phyto-600 fed pups. Animals were taken from litters whose
parents were diet matched and mated. These females continued on their parental treatment diets
from conception to the end of the experiment. Animal body weight was measured three times
weekly.
At two points in this experiment the animals underwent the Porsolt Forced Swim Test
(PFST). The first PFST was performed when animals were 115 days-old and measured the
effect of lifelong diet exposure on depressive-related behavior in young females. The second
PFST occurred when animals were 142 days-old and examined any changes in behavior as a
result of injected equol supplementation in the lifelong phyto-low diet animals. Behavioral
parameters recorded in these tests are mentioned in the PFST section and include mobility, swim
distance, swim speed, escape behaviors, etc. Before the second PFST, animals received four
daily injections (days 139-142). The Phyto-low animals received injections of 5 mg/kg (body
weight) equol in DMSO while the Phyto-600 animals received vehicle-DMSO injections.
Injections continued until the end of the experiment.
Animals were killed at 145 days of age. Animal body weight and white adipose tissue
deposition were recorded and trunk blood collected. Serum was assayed for serotonin and
isoflavones levels.
This experiment examined modeled two scenarios involving healthy, sexually intact
females capable of producing intestinal equol from daidzein when fed a diet rich in soy
isoflavones. The first situation examined solely the effect of a phytoestrogen-high (Asian) or a
phytoestrogen-low (Western) diet on study parameters in young adult females. The second
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situation examined isoflavone supplementation effects (via the equol injections) on the study
parameters following lifelong exposure to a Western diet.
The questions examined in this experiment are similar to those in experiment 1. First, do
phytoestrogens still have a visible effect in the presence of endogenous estrogens on study
parameters? Next, can equol injection successfully supplement a lifelong phytoestrogen-low
diet? Does age of equol administration change equol’s effects on study parameters? Finally,
does length of exposure matter?
Experiment 3: The objective of this experiment was to examine the effects of diet alone
on the study parameters (behavior, BW, WAT, etc) in gonadectomized, female rats that were
ovariectomized shortly after puberty.
Figure D

This experiment tested twenty-two ovariectomized female Long-Evans rats which were
purchased from Charles River Laboratories and shipped to our facilities at 50-55 days old.
Animal ovariectomy took place at the supplier when females were 40-45 days-old. While at the
supplier these animals were fed a diet containing approximately 200 ppm isoflavones (standard
in-house chow). Upon arrival at our facility the animals were switched to the Phyto-low diet
until approximately 80-85 days. Eleven animals were then switched to the Phyto-600 diet and
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fed this diet for approximately two weeks. The remaining animals continued on the Phyto-low
diet. Animal body weights were recorded daily.
When animals were approximately 100 days-old the animals were tested in the Porsolt
Forced Swim Test to examine the effect of diet alone in gonadectomized females. Behavioral
parameters recorded in these tests were the same as previous tests and are mentioned in more
detail in the PFST section.
Following the PFST the animals were sacrificed via decapitation at 100 days-old.
Animal body weight and white adipose tissue deposition were recorded and trunk blood
collected. Serum levels were only analyzed for isoflavone concentrations due to lack of serum
volume.
In the previous studies animals were exposed to the phytoestrogen-low diet, the
phytoestrogen-high diet, or both diets (see experiment 1). The animals switched to the
phytoestrogen-high diet during this experiment’s treatment were exposed to three diets: the
supplier diet (200 ppm), the Phyto-low diet (10-15 ppm) and the Phyto-600 (600ppm) diet.
While at the supplier these animals were fed a diet with 200 ppm isoflavones. Once at our
facility the animals were initially fed the Phyto-low (10ppm) diet and then later fed the Phyto600 diet. We do not believe that the supplier diet adversely affected this experiment.
This animal experiment modeled the dietary effects on young teenage girls who undergo
puberty and shortly thereafter undergo menopause due to ovariectomy. This experiment
examined the possibility that a modification in diet could help deal with the changes that occur as
a result of premature menopause. The two main questions posed by this study were first, can a
phytoestrogen diet have a positive effect on study parameters in young females who undergo
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ovariectomy shortly after menarche and, second, does timing of ovariectomy play a role in
female behavior and treatment response.
Experiment 4: This experiment examined the beneficial effects of diet and injection
supplement on the study parameters (BW, WAT, behavior, etc.) in ovariectomized female rats.
The animals in this study were all ovariectomized at an older age than in experiment 3. These
females were exposed lifelong to diet treatments (i.e. from conception) and as in previous
experiments the phytoestrogen-low diet animals were injected with equol supplement during
mid-age.
Figure E

Sixteen female, Long-Evans rats were selected from male and female rats mated by diet.
The pups remained life-long on the same diet as their parents. Eight of these animals came from
4 litters of pups fed the Phyto-low diet. The remaining eight animals were selected from 3 litters
of pups fed the Phyto-600 diet. Animals were weighed 3 times a week throughout treatment.
The female animals were ovariectomized at approximately 100 days by our laboratory
under the direction and guidance of the university veterinarian. Following ovariectomy the
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animals were allowed 7 weeks to recover from surgery before other treatment occurred. Details
for this procedure are located in the ovariectomy section above.
At three points in this experiment the Porsolt Forced Swim Test (PFST) was performed:
150 days, 200 days, and 220 days. The first PFST examined the effect of lifelong diet alone on
behavior in young ovariectomized females. Four days prior to the second PFST equol and
DMSO injections started (197-200 days). The second PFST examined the effect of injected equol
on the behavior of ovariectomized animals fed the lifelong Phyto-low diet. Injections continued
for the 3 weeks between the second PFST and the third PFST (Days 197-220). The third PFST
then examined extended exposure equol on the behavior of ovariectomized Phyto-low animals.
The second and third PFSTs also allowed us to compare short-term and long-term treatment
effectiveness of the equol injections. As in experiments 1 and 2 the Phyto-low fed animals
received injections of 5 mg/kg (body weight) equol in DMSO and the Phyto-600 fed animals
received vehicle-DMSO injections. Injections continued until the end of the experiment.
The animals were sacrificed at 222 days via decapitation. Animal body weight and white
adipose tissue deposition were recorded and trunk blood collected. Serum was collected for
serotonin and isoflavone analysis.
The animals in experiment 4 model young (mid twenties) women who undergo
menopause at a young age due to bilateral oophorectomy. This experiment examined the
possibility that a lifelong phytoestrogen diet could affect the behavioral and weight gain
symptoms which follow ovariectomy or early menopause. Short and long-term equol exposure
was then examined to see if supplementation would have any effect in younger ovariectomized
females. The two main questions examined here are first, does a phytoestrogen diet have a
positive effect on study parameters in females who undergo ovariectomy during young adulthood

25

and second, is this effect different than females ovariectomized in shortly after puberty
(experiment 3) or animals allowed to undergo natural ovarian failure (experiment 5).
Experiment 5: This experiment examined the effect of lifelong diet treatment exposure
and equol supplementation on study parameters when females undergo natural ovarian failure
(NOF). In the previous 4 experiments younger-aged animals of varying ovarian status were
examined. This experiment examined the effect of lifelong diet on these parameters in NOF
females and completes our examination of these effects.
Figure F

Fourteen female Long-Evans rats were used in these experiments. Six females were
selected from at least 3 litters fed the Phyto-low diet. Eight animals were selected from 3 litters
of animals maintained on the phyto-600 diet. As in previous experiments, the male and female
breeding rats were only mated with animals fed the same diet. The offspring/pups were
maintained lifelong on the same diet as their parents. The animals were weighed at selective
times throughout this experiment.
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The animals underwent natural ovarian failure (NOF) at approx. 300 days-old. NOF was
confirmed by vaginal histological examination of epithelial cells (Days 295-305). These
animals had blood collected at two times during this experiment. The initial collection occurred
prior to the first Porsolt Forced Swim Test (PFST). One half the animals from each group had
blood collected via tail veins to examine baseline serotonin and phytoestrogen levels. The second
blood collection occurred at tissue collection.
These females were exposed to two PFST, which occurred at 330 days, and 360 days.
The first PFST examined the effect of the lifelong dietary treatments on behavioral parameters
between treatment groups following natural ovarian failure. The second PFST examined the
effect of equol injection supplementation on the Phyto-low fed NOF animals. Injections
occurred for 7 consecutive days (354-360). The Phyto-low fed animals received injections of 5
mg/kg (body weight) equol in DMSO and the Phyto-600 fed animals received vehicle-DMSO
injections.
Following the second PFST, the animals were sacrificed via decapitation at
approximately 365 days of age. Body weight and white adipose tissue deposition were recorded
and trunk blood collected. Serum was analyzed for serotonin and phytoestrogen quantification.
These animals modeled older women either on a lifelong phytoestrogen-high (Asian) or a
phytoestrogen-low (Western) diet allowed to undergo natural ovarian failure. These females
were capable of producing intestinal equol from daidzein when fed a diet rich in soy isoflavones.
This experiment compared two scenarios. The first scenario examined females who simply have
a lifelong diet rich in phytoestrogens on the study parameters after NOF. The second scenario
examined equol supplementation after NOF following lifelong exposure to a phytoestrogen poor
diet to determine their influence on the study parameters.
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This study examined four questions. First, does lifelong exposure to a phytoestrogen-rich
diet decrease depression following natural ovarian failure? Second, is equol treatment more
effective in the absence of estrogens following NOF? Third, is there a difference in treatment
effectiveness on the study parameters between natural ovarian failure and ovariectomy? Finally,
do phytoestrogens have the ability to affect serotonin levels after NOF?
IACUC Approval
All methods associated with animals used were approved by the Institutional Animal
Care and Use Committee at Brigham Young University.
Statistical Analysis
Two-sample student t-tests with repeated measures were used to compare each of the
parameters examined between the two treatment groups in each experiment. All statistics were
run using the Minitab statistical software and a p-value less than 0.05 was considered significant.
All results are presented as MEANS ± SEM in all of the graphs and significant differences are
marked.
C. Results:
Figure G
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Experiment 1: Brief protocol summary – lifelong exposure from conception to the Phyto-low
diet in intact females. Diet change at 120 days old (one-half of the animals were switched to
Phyto-600 diet while the other half remained on the Phyto-low diet). 1st PFST at 120 days old
prior to diet change; 2nd PFST at 150 days old; equol injections occurred from 196-210 days old
with 3rd PFST at 200 days-old. Tissue collection occurred at age 210 days.
The effects of an isoflavone rich diet on animal body weight, white adipose tissue (WAT)
deposition, behavioral parameters, and serum isoflavone and serotonin levels in intact females
are described. These data examined the effects of isoflavones in the presence of naturally
occurring estrogens from ovarian sources.
Body Weight and WAT
The effects of dietary isoflavones on animal body weight and the changes in animal body
weight are displayed in Figure 1. Female body weight values were analyzed prior to each
Porsolt forced swim test (PFST) and at tissue collection; these values are reported in Table 1.
Baseline body weights at the time of the first PFST (@ 120 days old) were not significantly
different between treatment groups (Figure 2A). Following diet change where half of the
animals were switched to the Phyto-600 diet, the Phyto-600 fed animals experienced an
immediate decrease in weight gain. When compared at the second PFST (@150 days old), the
Phyto-600 animals weighed significantly less than the Phyto-low animals (p<0.001; Phyto-low
mean = 354.0 ± 5.7 grams, Phyto-600 mean = 326.4 ± 5.4 grams; Figure 3A). The Phyto-low
animals lost weight following equol injection prior to the third PFST. However, four days of
equol injection were insufficient to remove the significant differences in body weight between
treatment groups. The Phyto-600 animals still maintained significantly lower body weights
(p<0.001; Phyto-low mean = 375.6 ± 7.3grams, Phyto-600 mean = 332.6 ± 6.7 grams; Figure
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4A). Animal body weight at the end of the experiment (Phyto-low mean = 369.9 ± 7.3 grams,
Phyto-600 mean = 331.3 ± 6.4 grams) and white adipose tissue (WAT) deposition (Phyto-low
mean = 20.1 ± 1.7 grams, Phyto-600 mean = 13.1 ± 1.2 grams) were significantly greater in the
Phyto-low animals compared to the Phyto-600 animals (p<0.001 and p<0.003 respectively;
Figure 5A and B). When standardized to body weight, the WAT/BW ratios were also
significantly higher in the Phyto-low animals (p<0.012, Phyto-low mean = 0.054 ±0.004, Phyto600 mean = 0.039 ± 0.003; Figure 5C).
Porsolt Forced Swim Tests
There were no significant differences in baseline animal behavioral parameters in the first
PFST (Figure 2B-D). The second PFST also demonstrated no significant behavioral differences
between treatment groups (Figure 3B-D). In the third PFST, the Phyto-600 animals released
significantly more boli than the Phyto-low animals (p<0.014, Phyto-low mean = 3.1 ± 1.7,
Phyto-600 mean = 5.3 ± 1.2). However, there were no significant differences in animal
performance between treatment groups for any other behavioral parameters. Notably in both
experiments 1 and 4, the immobility interval from the second PFST to the third PFST
dramatically increased.
Serum Isoflavone Levels
Serum isoflavone levels were measured with gas chromatography/mass spectrometry.
Figure 21A illustrates the isoflavone serum levels and types obtained from the 210 day-old,
intact females fed either the Phyto-600 or Phyto-low diet. Serum levels of daidzein (Phyto-low
mean = 4.8 ± 0.7 ng/ml, Phyto-600 mean = 34.9 ± 6.7 ng/ml), genistein (Phyto-low mean = 8.1 ±
0.6 ng/ml, Phyto-600 mean = 45.3 ± 8.4 ng/ml), and equol (intestinal isoflavonoid metabolite of
daidzein)( Phyto-low mean = 439.1 ± 80.5 ng/ml, Phyto-600 mean = 932.3 ± 121.4 ng/ml) were
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all significantly lower in the Phyto-low animals (p<0.001-0.007). Equol was the major
circulating phytoestrogen in both treatment groups while genistein and daidzein represented
lower percentages of the total phytoestrogen content. Serum values are displayed in Table 2.
Although the Phyto-low animals received equol injections for four consecutive days, the serum
levels of equol in these animals were still less than half the levels of equol found in the animals
fed the Phyto-600 diet where natural conversion of equol took place.
Serum Serotonin Levels
Circulating serotonin levels were determined by ELISA. Serum serotonin values were
within normal ranges (as described in the vendor’s assay kit values). Although there was a slight
increase in the serum serotonin concentration of the Phyto-low animals injected with equol, there
were no significant differences in serum serotonin levels between treatment groups. Notably,
these values were obtained following equol injection and tissue collection. Pre-equol injection
values for serotonin were not collected. Serum serotonin values are shown in Table 3.
Overall Results
These results demonstrate that an isoflavone rich diet decreases animal body weight gain
and WAT deposition. However, aside from increased boli excretion in the third PFST, there
were no significant behavioral differences between treatment groups. While equol injection
increased serum equol levels in the Phyto-low fed animals, these levels were still significantly
lower than the dietary values obtained by the Phyto-600 fed animals. Animal serum serotonin
levels were not significantly different between treatment groups. While an isoflavone diet does
have some positive benefits this diet does not appear to affect animal behavior when naturally
occurring estrogens are also present in intact animals.
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Experiment 2: Brief protocol summary – lifelong exposure from conception to either a Phytolow or Phyto-600 diet. 1st PFST at 115 days old. Equol injections for seven consecutive days
(139-145); 2nd PFST at 142 days old. Tissue collected at 145 days old.
Experiment 2 examined the effects of lifelong diet on the study parameters in intact,
young adult females. Equol effectiveness, either intestinally produced from the diet or
administered via s.c. injection, in the presence of naturally occurring estrogens was tested.
Length of dietary treatment exposure and age of isoflavone administration were also
investigated.
Body Weight and WAT
Changes in animal body weight from 80-142 days-old are shown in Figure 6. Body
weights were tested for significance at the first and second forced swim tests (PFST) and at
animal sacrifice. These values, as well as the WAT values, are shown in Table 1 and are
illustrated in Figures 7A, 8A and 9A. Throughout this experiment the Phyto-600 animals
displayed lower average body weights than the Phyto-low animals, though this difference was
not significant. WAT values also tended to be lower in the Phyto-600 animals than the Phytolow animals; however, these differences were not significant (Figure 9B-C).
Porsolt Forced Swim Tests
During the first PFST (@115 days old), the Phyto-600 animals excreted significantly
more boli than the Phyto-low animals (p<0.037, Phyto-low mean = 2.5 ± 0.4, Phyto-600 mean =
3.8 ± 0.3). Tendencies for swimming further, faster and longer were seen in the Phyto-600
animals. However, these tendencies were not significant and no other significant behavioral
differences were observed between treatment groups (see Figure 7B-D). During the second
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PFST (@142 days old), following one week of equol injections, there were no significant
behavioral differences between groups and no apparent trends (see Figure 8B-D).
Serum Isoflavone Levels
Isoflavone levels were determined by gas chromatography/mass spectrometry for serum
obtained from 145 day-old females and are illustrated in Figure 21B. Serum levels of daidzein
(Phyto-low mean = 7.0 ± 0.8 ng/ml, Phyto-600 mean = 30.5 ± 5.1 ng/ml), genistein (Phyto-low
mean = 7.1 ± 1.4 ng/ml, Phyto-600 mean = 32.1 ± 11.8 ng/ml), and equol (Phyto-low mean =
345.5 ± 97.1 ng/ml, Phyto-600 mean = 753.5 ± 76.6 ng/ml) were significantly lower in the
Phyto-low animals compared to the Phyto-600 animals (p<0.001-0.008). Although the Phytolow fed animals were injected with equol for 4 consecutive days the serum levels of equol in
these animals were still less than half the levels of equol found in animals fed the Phyto-600 diet
where intestinal conversion of equol took place. Equol was the primary phytoestrogen present,
while both genistein and daidzein represented smaller percentages of the total serum
phytoestrogen content. Serum isoflavone values are displayed in Table 2. As seen in experiment
1, diet appears to be more effective than injection in obtaining higher serum equol levels in intact
females.
Serum Serotonin Levels
Serotonin levels were measured using ELISA and are shown in Table 3. All values
obtained were within the normal range described in the vendor’s kit. There were no significant
differences in serum serotonin concentrations between treatment groups. Like experiment 1, the
equol-injected Phyto-low animals tended to have higher serotonin levels than the Phyto-600
animals, but these differences were not significant. These values were also obtained following
equol administration; prior serotonin concentrations are not known.
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Overall Results
The Phyto-600 fed animals tended to have lower body weights and WAT content;
however, these differences were never significant. The diet change during young adulthood in
Experiment 1 appears to be more effective than the lifelong dietary treatment in Experiment 2 in
producing lower body weights in intact females. Behavior was also not significantly affected
between treatment groups. While equol values were significantly higher in the Phyto-600
animals there were no significant differences in serotonin levels between treatment groups.
Injected equol values were significantly lower than intestinally produced circulating serum
values. However, neither intestinally produced nor injected equol were effective in the presence
of estrogens produced from ovarian sources during this interval from birth to 145 days of age.
Experiment 3: Brief protocol summary – All ovariectomized animals were fed a Phyto-low diet
from 60-85 days of age after arrival at BYU. Diet change at 85 days old (one-half of the animals
were fed a Phyto-600 diet while the other half remained on the Phyto-low diet). At 100 days old
PFST was performed followed by tissue collection.
Experiments 1 and 2 demonstrate that isoflavones are not very effective when estrogens
are also present. Experiment 3 examined the effects, on the study parameters, of isoflavone-rich
or poor diets in young ovariectomized females with low estrogen levels. This experiment also
introduced the possibility that timing of ovariectomy may also play a role in animal behavior and
treatment response.
Body Weight and WAT
Dietary treatment lasted for approximately two weeks. Changes in animal body weight
are illustrated in Figure 10 and specific values are displayed in Table 1. Throughout the
experiment there were no significant differences in body weight between treatment groups.
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However, the Phyto-600 animals tended to weigh less following the diet change at 85 days
(Figure 10 and 11A). Animal WAT deposition was lower in Phyto-600 animals (p<0.001;
Phyto-low mean = 16.0 ± 0.9 grams, Phyto-600 mean = 11.4 ± 0.7 grams) than the Phyto-low
animals though when normalized to body weight this significance disappeared (p<0.086) (Figure
12B-C).
Porsolt Forced Swim Tests
There were no significant differences between treatment groups for any of the behavioral
study parameters in the Porsolt forced swim test (see Figure 11B-D). This could be due to the
brief duration of the treatment.
Serum Isoflavone Levels
Serum isoflavone levels were measured via gas chromatography/mass spectrometry and
are illustrated in Figure 21C. In this experiment, the serum levels of daidzein (Phyto-low mean =
3.1 ± 0.3 ng/ml, Phyto-600 mean = 38.2 ± 7.0 ng/ml), genistein (Phyto-low mean = 5.3 ± 1.1
ng/ml, Phyto-600 mean = 48.5 ± 8.6 ng/ml), and equol (Phyto-low mean = 4.1 ± 0.4 ng/ml,
Phyto-600 mean = 495.6 ± 33.3 ng/ml) were also significantly lower in Phyto-low fed animals
than the Phyto-600 fed animals (p<0.001). Serum levels of genistein and daidzein represented
lower percentages of the total phytoestrogen contend. Equol was the primary phytoestrogen
present. Isoflavone levels of daidzein, genistein and equol were not significantly different from
each other in the Phyto-low animals. Actual serum values are shown in Table 2.
Overall Results
As shown in experiment 1, switching to an isoflavone rich diet may decrease body weight
and WAT deposition. However, treatment longer than two weeks may be required to obtain
statistical significance in young ovariectomized females. In this study, even though there is an
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absence of naturally occurring estrogens, this short-term exposure to isoflavones does not appear
to affect animal behavior. This could be due to the lack of sufficient prior estrogen exposure in
the animal as these females were ovariectomized shortly after puberty (45-50 days old).
Experiment 4: Brief protocol summary – lifelong exposure from conception to either a Phytolow or Phyto-600 diet. All animals were ovariectomized at approximately 100 days old. 1st
PFST at 150 days old; equol injections started four days prior to 2nd PFST at 200 days old and
continued until end of experiment. 3rd PFST at 220 days old. Tissue collection at 222 days old.
This experiment tested females that were ovariectomized at an older age than the females
in experiment 3. This difference examined the possibility that treatment response could be
dependent on timing of ovariectomy. This experiment also tested the idea that a lifelong
phytoestrogen-rich diet could positively affect performance in the study parameters of females
that underwent ovariectomy during young adulthood.
Body Weight and WAT
Figure 13 illustrates the changes in animal body weight from ovariectomy to tissue collection
(85-222 days-old) between treatment groups. These animals underwent three PFSTs; animal
body weights were tested for significance at each of these points in the experiment. This data
along with the ending body weight and WAT values are displayed in Table 1. When animals
were ovariectomized at approximately 100 days old the Phyto-600 animals had significantly
lower body weights (p<0.039; Phyto-low mean = 306.5 ± 8.3 grams, Phyto-600 mean = 278.6 ±
9.0 grams). The Phyto-600 animals continued to have significantly lower body weights through
the first (Phyto-low mean = 431.0 ± 12.6 grams, Phyto-600 mean = 371.5 ± 15.4 grams) and
second (Phyto-low mean = 487.1 ± 20.6 grams, Phyto-600 mean = 414.6 ± 12.3 grams) forced
swim tests (p<0.01 and p<0.021 respectively; Figures 14A and 15). Although, equol injections
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started four days prior to the second PFST (@ 200 days of age), this did not significantly affect
the Phyto-low animal body weights. Animal body weights were no longer significantly different
from each other at 214 days old. The Phyto-600 animals still had lower average body weights
but these values were no longer significant (Figure 16A). The Phyto-low animals displayed
decreasing body weights from the start of equol injection to animal sacrifice (Figure 13). If this
treatment continued longer it is possible that even the Phyto-600 animals’ trend for lower body
weights would have disappeared. Ending body weights, WAT and WAT/BW were not
significantly different between groups. However, at this point, the Phyto-600 animals still
tended to have lower values for these parameters than the Phyto-low animals (Figure 17).
Porsolt Forced Swim Tests
In the first PFST (@ 150 days of age), the Phyto-600 animals tended to swim slightly longer,
further and faster and tended to dive more and excrete more boli. However, these differences
were not significant (Figure 14 B-D). During the second PFST (@ 200 days old), there were no
significant differences between these behavioral parameters. The only point of significance
noted during the second PFST was the number of boli excreted by the Phyto-600 animals. This
value was significantly greater in the Phyto-600 fed animals than the Phyto-low fed animals
(p<0.001; Phyto-low mean = 3.9 ± 0.4, Phyto-600 mean = 6.75 ± 0.5). The third PFST (at 220
days old) had no significant differences between treatment groups for any behavioral parameters
and there were no visible trends (Figure 16B-D).
Serum Isoflavone Levels
Figure 21D illustrates the serum isoflavone levels as quantified via gas
chromatography/mass spectrometry. Serum levels of genistein (Phyto-low mean = 8.3 ± ng/ml,
Phyto-600 mean = 36.0 ± 7.8 ng/ml) and daidzein (Phyto-low mean = 8.0 ± 1.7 ng/ml, Phyto-600
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mean = 40.4 ± 9.2 ng/ml) were significantly lower in the Phyto-low fed animals than in the
Phyto-600 animals (p<0.005 and 0.006 respectively). However, serum levels of equol were
significantly higher (at least 300 ng/ml higher) in the Phyto-low fed animals than in the Phyto600 fed animals (p<0.002; Phyto-low = 779.2 ± 63.7 ng/ml and Phyto-600 = 415.1 ± 64.9
ng/ml). Equol was the primary phytoestrogen present in animal serum. Genistein and daidzein
both represented lower percentages of total phytoestrogen content. All mean serum values are
shown in Table 2.
Serum Serotonin Levels
As in all three of the previous experiments, there were no significant differences between
serum serotonin levels for the Phyto-600 and the Phyto-low animals. Serotonin levels were
quantified via Elisa and these values are shown in Table 3. These levels are within the normal
range set by the vendor’s kit.
Overall Results
In animals ovariectomized during young adulthood, lifelong isoflavone diet significantly
decreased body weight gain. However, there were still no apparent behavioral effects other than
increased boli excretion. Unlike previous experiments, the equol injected animals had higher
equol levels than the intestinally produced equol of the Phyto-600 animals. Similar to the equol
concentrations, serotonin levels were also the opposite of the previous experiments. The
relationship between serum levels of serotonin and equol still needs to be further examined.
Overall, ovariectomy appears to change how the diet affects the body. It appears that the later
the ovariectomy, the more effective the dietary treatment.
Experiment 5: Brief protocol summary – lifelong exposure from conception to either a Phytolow or Phyto-600 diet. All animals experienced natural ovarian failure (NOF) at approximately
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300 days old. 1st PFST at 330 days old; equol injections started 7 days prior to 2nd PFST at 360
days old in the Phyto-low group only. Tissue collection at 365 days old.
Ovarian status causes animals to respond differently to isoflavone rich or poor diets. This
last experiment tested the effects of lifelong exposure from conception to a phytoestrogen-rich
diet on study parameters in animals that underwent natural ovarian failure (NOF). This
experiment investigated the effectiveness of equol treatment in the absence of estrogens
following NOF. Experiment 5 also examined equol’s ability to affect serum serotonin levels.
This last experiment allowed for comparisons between treatment response and ovarian status
(intact, ovariectomized or NOF).
Body Weight and WAT
Animal body weight measurements were only recorded at specific points during this
experiment. These major points and corresponding values are displayed in Table 1. At the first
PFST (@ 330 days old), which occurred approximately a month after NOF, the Phyto-600 fed
animals had significantly lower body weights (Phyto-low mean = 526.5 ± 25.9 grams, Phyto-600
mean = 469.1 ± 21.3 grams) than the Phyto-low animals (p<0.05; Figure 18A). One week prior
to the second PFST, the Phyto-low animals were injected with equol as mentioned previously.
When measured at the second PFST (@ 360 days old), animal body weights were no longer
significantly different between treatment groups (Figure 19A). However, WAT deposition was
still significantly greater in the Phyto-low fed animals (Phyto-low mean = 32.1 ± 3.9 grams,
Phyto-600 mean = 23.3 ± 2.7 grams) and this trend continued even when WAT was normalized
to body weight WAT/BW (p<0.05; Phyto-low mean = 0.063 ± 0.006, Phyto-600 mean = 0.049
±0.005; Figure 20B and 20C).
Porsolt Forced Swim Test
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In the first PFST (@ 330 days old), time immobile (Phyto-low mean = 401.5 ± 10.3 (s),
Phyto-600 mean = 345.9 ± 14.8 (s)), swimming distance (Phyto-low mean = 7.3 ± 0.8 (m),
Phyto-600 mean = 12.5 ± 1.0 (m)), and overall average speed (Phyto-low mean = 0.015 ± 0.002
(m/s), Phyto-600 mean = 0.026 ± 0.002 (m/s)) were significantly higher in the Phyto-600 fed
animals compared to the Phyto-low fed animals (p<0.005; Figure 18B-D). These animals also
dove significantly more often (p<0.005; Phyto-low mean = 0.8 ±0.4, Phyto-600 mean = 2.6 ±
0.6) indicating escape behaviors. This is the first experiment where a dramatic and significant
difference between lifelong diets occurred. Equol injection was also the most effective in this
experiment. Following equol injection, there were no significant differences observed between
treatment groups for any of the behavioral parameters in the second PFST (@ 360 days old)
(Figure 19B-D).
Serum Isoflavone Levels
Serum isoflavone levels were calculated using gas chromatography/mass spectrometry.
All isoflavone values are shown in Table 2 and the differences are illustrated in Figure 21E.
Serum levels of daidzein (Phyto-low mean = 3.1 ± 0.3 ng/ml, Phyto-600 mean = 34.2 ± 6.5
ng/ml), genistein (Phyto-low mean = 4.6 ± 0.8 ng/ml, Phyto-600 mean = 25.2 ± 5.0 ng/ml), and
equol (daidzein’s intestinal metabolite)(Phyto-low mean = 4.0 ± 0.4 ng/ml, Phyto-600 mean =
321.6 ± 10.0 ng/ml) were all significantly lower in the Phyto-low animals compared to the
Phyto-600 animals prior to the first PFST (p<0.001). The concentrations of these phytoestrogens
were not significantly different from one another in the Phyto-low animals. In the Phyto-600
animals, equol formed the highest percentage of all of the phytoestrogen content. Following the
second PFST only serum levels of daidzein (Phyto-low mean = 3.1 ± 0.3 ng/ml, Phyto-600 mean
= 34.2 ± 6.5 ng/ml) and genistein (Phyto-low mean = 3.7 ± 0.5 ng/ml, Phyto-600 mean = 25.2 ±
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5.0 ng/ml) were significantly lower in the Phyto-low animals compared to the Phyto-600 animals
(p<0.001). Serum equol values were not significantly different between treatment groups
following the second PFST. In fact, the equol values were slightly higher in the Phyto-low
animals (Phyto-low = 376.3 ± 92.9 ng/ml and Phyto-600 = 321.6 ± 10.0 ng/ml). Following the
second PFST, serum equol values formed the primary serum phytoestrogen for both treatment
groups. Genistein and daidzein represented significantly lower percentages of total
phytoestrogen content.
Serum Serotonin Levels
Serum serotonin levels were quantified using ELISA. All serotonin values are shown in
Table 3 and are within the normal range stated by the vendor’s kit. The Phyto-low fed animals
had lower serum serotonin values prior to the first PFST than the Phyto-600 fed animals (Phytolow = 202.0 ± 29.0 ng/ml and Phyto-600 = 338.2 ± 38.7 ng/ml). However, statistical significance
could not be numerically obtained between treatment groups due to the low number of animals
whose blood was drawn prior to equol injections (n=3 Phyto-low and n=4 Phyto-600).
Following equol injection, the Phyto-low serotonin values were slightly higher than the Phyto600 values (Phyto-low = 340.0 ± 44.1 ng/ml and Phyto-600 = 313.6 ± 59.7 ng/ml). Equol
treatment significantly increased serum serotonin levels in the Phyto-low animals (p<0.042; see
Figure 22). Even though serotonin levels were not statistically significant prior to equol
administration, the Phyto-600 values were over 100 ng/ml greater (or 1.7 times higher) than the
Phyto-low values. Equol injection also appears to increase the serum levels of serotonin (Figure
23).
Overall Results
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After natural ovarian failure, a lifelong isoflavone rich diet is able to decrease body
weight and WAT deposition as well as depressive-related behavioral parameters. Isoflavone
treatment is much more effective in the absence of estrogens following normal reproductive
estrogen exposure. Equol supplementation appears to compensate for a lifelong phytoestrogenpoor diet. Serum levels of the isoflavonoid equol appear to affect both animal immobility as an
anti-depressive agent and increase serum serotonin levels. Overall, when comparing all five
experiments reported here, isoflavone treatment (either dietary or injected) in animals that
undergo NOF is the most effective on study parameters.
D. Discussion
This study demonstrated that isoflavones whether administered through the diet or via
injection effectively decrease body weight and white adipose tissue deposition in females
regardless of age or ovarian status. Experiments 1, 4, and 5 demonstrated dietary isoflavones
decreased body weights in animals fed the isoflavone rich Phyto-600 diet. Experiments 1, 2, 4,
and 5 demonstrated that equol injection also decreased body weight. Once equol injections
began in the Phyto-low fed females, immediate weight loss was seen. Experiments 4 and 5 both
received treatment for a period sufficient to decrease the Phyto-low fed female animal body
weights until there were no significant differences between them and the Phyto-600 animals.
These results are similar to those previously published in male rats (122).
Whether isoflavones were injected or consumed in the diet, the primary serum isoflavone
present in each case was equol (Table 2). The resulting decrease in body weight and white
adipose tissue deposition indicates that equol has potential as an anti-obesity treatment. Previous
studies have demonstrated that both genistein and daidzein, when administered alone, have antiobesity effects. Genistein appears to mimic estrogenic activity and alters food intake, body
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weight, adipose tissue deposition, and lipid uptake into adipocytes by decreasing lipoprotein
lipase (LPL) activity (42,43,123-125). Daidzein also appears to decrease LPL activity, increase
lipolysis, and inhibit adipogenesis via estrogenic pathways (123,126,127). ERβ has been shown
in previous studies to be involved in anti-obesity effects (128,129). While equol’s mechanism
of action as an anti-obesity is still unknown, equol’s affinity for ERβ suggests a possible
estrogenic pathway (74,96). Conversely, unpublished data sets from our laboratory suggest that
the R-equol isomer may be responsible for the majority of the anti-obesity actions. Additionally,
a previously published abstract by our lab further supports equol’s estrogenic actions because
equol’s actions can be blocked by an ER antagonist (130). Tamoxifen, a SERM able to
antagonize ERs (75) is able to block the positive influence of equol in human monolayer
fibroblasts (130).
This study also demonstrated that equol decreases depressive-related behavior in females
that undergo natural ovarian failure. Before receiving equol injections the experiment 5 Phytolow animals demonstrated greater immobility in the PFST and decreased serum serotonin levels.
Equol administration significantly decreased the time spent immobile in the PFST and
significantly increased serum serotonin levels in these animals. This study is the first to report
equol’s effectiveness as an antidepressant using the PFST. The testing of other isoflavones such
as quercitin or resveratrol in the PFST, while few in number, demonstrate that isoflavones have
potential as antidepressant treatments (131,132).
Again, while equol’s mechanism of action as an antidepressant is not known, equol’s
estrogenic affinity for ERβ indicates that it has the ability to affect behavioral changes in the
brain. ERβ is found in four brain regions associated with behavioral and mood disorders, the
frontal cortex, the amygdala, the hippocampus, and the hypothalamus (47,133-135). A previous
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study demonstrated that following dietary isoflavone exposure in young, intact, female LongEvans rats, equol levels in the frontal cortex, the hippocampus, the hypothalamus, and the
amygdala increased demonstrating a greater ability for equol to affect these regions (136). The
highest levels of equol concentration were located in the frontal cortex where equol makes up
round 50% of the isoflavone concentration. Equol levels in the amygdala, hypothalamus, and
hippocampus were significantly lower than the frontal cortex levels. However, in each of these
regions, equol is the primary isoflavone (80-90% of total isoflavone content) (136). The location
and relative concentration of equol in these brain regions indicates that equol both collects in
these regions and could also initiate estrogenic actions due to the presence of ERβ.
Previous studies have demonstrated that ERβ is involved in animal expression of both
anxiety and depressive-related behaviors (47,113,134,137). A study performed in ERβ knockout
mice demonstrated ERβ is involved in anxiety behaviors as the knockout mice demonstrate
increased anxiety (137). Others studies have shown that administering an ERβ specific agonist
decreases depressive related behavior (113). These studies indicate that ERβ is important in
regulating mood disorders. Additionally, because isoflavones in general demonstrate higher
binding affinities for ERβ (96), these chemicals could potentially regulate mood using estrogenic
pathways. Finally, unpublished data sets from our laboratory suggest that the R-equol isomer is
also involved in treating anxiety and depression. The R-equol isomer is more effective than
racemic equol which is more effective than the S-equol isomer in treating anxiety. R-equol is
able to bind ER subtypes using molecular and biochemical mechanisms that are currently
unknown
Estrogens are also known to affect behavioral hormones such as serotonin. Estrogens
affect serotonin levels, as well as serotonin receptor expression, and function (50). As
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mentioned above these effects are likely initiated via ERβ. In particular, the raphe nucleus of the
brain which produces serotonin specifically expresses ERβ indicating that not only do estrogens
potentially affect hormone levels but that isoflavones have this same potential (138). As
demonstrated in Experiment 5, equol injection significantly alters serum serotonin levels. This
combined with the expression of ERβ in the raphe nucleus indicates a possible pathway for equol
to affect serotonin concentrations.
In humans, depression is associated with decreased serotonin levels; depressed
individuals have significantly lower levels of serotonin than non-depressed individuals (114,139141). Furthermore, the relationship between serum and CSF serotonin levels indicates potential
for decreased serum serotonin concentrations to signify depression (114). One study in humans
displayed that serotonin levels in non-depressed individuals were 1.6 times greater than
depressed individuals (141). Another human study performed in depressed individuals
demonstrated that administration of the antidepressant fluoxetine increased serum serotonin
levels in depressed patient by 1.7-fold (142). Both of these results were seen in the experiment 5
females. Prior to equol injection and the first PFST, the Phyto-600 female serum serotonin
values were 1.7 times greater than the Phyto-low females. The first PFST then demonstrated that
the Phyto-low females expressed increased depressive-related behavior compared to the Phyto600 females. Subsequent equol injections increased the serum serotonin levels in the Phyto-low
females by 1.7-fold, similar to the results for the fluoxetine study in humans (142). This
indicates that, although, in this experiment the serum values prior to the first PFST had an
insufficient number of females for statistical significance, this finding can still be considered
pertinent due to the similar values found in human studies. In summary, equol’s ability to bind
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ERβ, ERβ’s locations in the brain, and the increased serum serotonin levels with decreased time
immobile demonstrated in this study all indicate equol’s potential as an antidepressant.
However, the use of animals with varying ovarian status in this study also demonstrated
that dietary isoflavones or equol alone may have limited use as antidepressant treatments. For
instance, ovarian status plays a role in equol treatment effectiveness. Equol is ineffective at
decreasing depressive-related behavior in intact females or females ovariectomized shortly after
puberty. Experiments 1-4 all displayed no significant differences in depressive-related behavior
as measured by the PFST.

Intact females have endogenous levels of estrogens that appear to

hide or negate any behavioral effects either isoflavones or equol alone might have in these
animals. Furthermore, the ovariectomized animals in these experiments were ovariectomized
shortly after puberty and perhaps did not have sufficient estrogen exposure to have behavioral
effects. Only experiment 5 showed any significant behavioral differences following lifelong
endogenous estrogen exposure and natural ovarian failure. Both lifelong dietary isoflavones and
equol injection treatment were able to clearly alter animal depressive-related behavior as
measured by the Porsolt forced swim test. Animals that were exposed from conception to natural
ovarian failure to an isoflavone rich diet displayed fewer depressive-related behaviors in the
Porsolt forced swim test compared to animals on a lifelong isoflavone poor diet. Additionally,
equol injection in the females on the lifelong isoflavone poor diet significantly decreased
depressive-related behaviors in the Porsolt forced swim test (Figure 23). From this study it
appears that while equol has potential as an antiobesity treatment regardless of ovarian status or
mode of administration, as an antidepressant equol appears to be effective only following natural
ovarian failure in this animal model of menopause.
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Menopause/ovarian failure is a normal part of the aging process and all normal cycling
females will one day undergo this condition (143). However increasing numbers of women are
entering menopause prematurely due to either bilateral oophorectomy or cancer treatment (7,12).
Severity of menopausal symptoms and the risk of certain diseases and conditions increase as age
of menopause decreases (30). This study examined depression and obesity which are symptoms
associated with menopause that affect both health and quality of life (19,46). As mentioned
earlier, central obesity increases risk for many menopausal conditions such as cardiovascular
disease or breast cancer (39,45),while, depression causes menopausal symptoms and associated
conditions feel and appear more serious (46). Furthermore, the five experiments in this study
indicate that timing and manner of ovarian failure can affect treatment response. It appears that
as an anti-obesity dietary treatment, isoflavones are effective at decreasing body weight
regardless of ovarian status. However, as an antidepressant, dietary isoflavones appear to be
effective only following natural menopause at which point supplemental equol while consuming
a low soy diet appears to be as effective.
E. Summary:
The current study demonstrates that equol is able to decrease body weight, abdominal
WAT, and depressive-related behavior in this animal model regardless of age or ovarian status.
However, equol’s effectiveness as an antidepressant in this model may be dependent upon the
changes/timing of ovarian status with aging. This study demonstrated that equol’s beneficial
effects are most clearly seen in female rats that have undergone natural ovarian failure. Further
studies determining equol’s exact mechanisms of action and potential as an antidepressant still
need to be performed.
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Tables
Table 1. Body Weight Prior to Each Porsolt Test and Tissue Collection Body Weight, WAT and WAT/BW (grams, MEAN ± SEM)_
Experiment Diet
1st PFST
2nd PFST
3rd PFST
T.C. BW
T.C. WAT
WAT/BW
____________________________________________________________________________________________________________
1

Phyto-low
330.4 ± 5.9
354.0 ± 5.7** 375.6 ± 7.3** 369.9 ± 80.4** 20.1 ± 1.7*
0.054 ± 0.004*
Phyto-600
327.6 ± 5.1
326.4 ± 5.4
332.6 ± 6.7
331.3 ± 6.4
13.1 ± 1.2
0.039 ± 0.003
____________________________________________________________________________________________________________
2

Phyto-low
318.5 ± 15.0
338.2 ± 16.5
N/A
335.1 ± 15.8
16.1 ± 2.4
0.047 ± 0.005
Phyto-600
301.1 ± 12.9
323.2 ± 16.3
322.3 ± 15.2
11.9 ± 2.5
0.036 ± 0.006
____________________________________________________________________________________________________________
3

Phyto-low
336.0 ± 7.3
N/A
N/A
336.0 ± 7.3
16.0 ± 0.9
0.042 ± 0.005
Phyto-600
319.1 ± 6.8
N/A
N/A
319.1 ± 6.8
11.4 ± 0.7#
0.032 ± 0.004
____________________________________________________________________________________________________________
4

Phyto-low
431.0 ± 12.6* 487.1 ± 20.6* 454.4 ± 56.6
453.5 ± 19.3
23.4 ± 5.1
0.049 ± 0.009
Phyto-600
371.5 ± 15.4
414.6 ± 12.3
417.0 ± 57.8
413.6 ± 20.2
20.2 ± 2.0
0.048 ± 0.010
____________________________________________________________________________________________________________
5

Phyto-low
526.5 ± 25.9* 507.9 ± 21.2
N/A
507.9 ± 21.2
32.1 ± 3.9#
0.063 ± 0.006#
Phyto-600
469.1 ± 21.3
472.1 ± 19.6
N/A
472.1 ± 19.6
23.3 ± 2.7
0.049 ± 0.005
____________________________________________________________________________________________________________
Comparing diet and/or equol treatments within a column category: ** p<0.001; * p<0.01; # p<0.05; PFST = Porsolt forced swim test,
N/A = not assayed, T.C. = tissue collection; BW = body weight; WAT = white adipose tissue deposition,
= time of equol
injection.
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Table 2. Serum Levels of Isoflavones, Genistein and Daidzein, and Isoflavonoid Equol (all values in ng/ml ± 1.0)_
Experiment
Diet
Genistein
Daidzein
Equol
Total (G+D+E)
____________________________________________________________________________________________
1

Phyto-low
8.1 ± 0.6*
4.8 ± 0.7*
439.1 ± 80.5*
452.0 ± 80.4*
Phyto-600
45.3 ± 8.4
34.9 ± 6.7
932.3 ± 121.4
1012.5 ± 135.5
____________________________________________________________________________________________
2

Phyto-low
7.1 ± 1.4*
7.0 ± 0.8*
345.5 ± 97.1*
359.5 ± 96.5*
Phyto-600
32.1 ± 11.8
30.5 ± 5.1
753.5 ± 76.6
816.1 ± 81.0
____________________________________________________________________________________________
3

Phyto-low
5.3 ± 1.1*
3.1 ± 0.3*
4.1 ± 0.4*
12.4 ± 1.4*
Phyto-600
48.5 ± 8.6
38.2 ± 7.0
495.6 ± 33.3
582.3 ± 31.2
____________________________________________________________________________________________
4

Phyto-low
8.3 ± 0.4*
8.0 ± 1.7*
779.2 ± 60.4 #
792.2 ± 63.7 #
Phyto-600
36.0 ± 7.8
40.4 ± 9.2
415.1 ± 64.9
491.5 ± 76.3
____________________________________________________________________________________________
5

Phyto-low
Before
4.6 ± 0.8*
3.1 ± 0.3*
4.0 ± 0.4*
11.1 ± 1.2*
After
3.7 ± 0.5*
3.1 ± 0.3*
376.3 ± 92.9
383.3 ± 92.0
Phyto-600
Before
31.4 ± 6.3
36.1 ± 7.1
339.7 ± 13.7
407.3 ± 27.0
After
25.2 ± 5.0
34.2 ± 6.5
321.6 ± 10.0
381.0 ± 21.0
____________________________________________________________________________________________
* Phyto-low value significantly lower than Phyto-600 value; # Phyto-low value significantly higher than Phyto-600
value; ** Phyto-low Before value significantly lower than After value; Before refers to serum measured prior to 1st
Porsolt test; After refers to serum measured after 2nd Porsolt test.
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Table 3 Serum Serotonin Levels (all values in ng/ml ± 1.0)
Experiment
Diet
Serotonin
_______________________________________________
1

Phyto-low
544.9 ± 205.9
Phyto-600
444.5 ± 168.0
_______________________________________________
2

Phyto-low
374.0 ± 141.4
Phyto-600
352.9 ± 133.4
_______________________________________________
3

Phyto-low
N/A
Phyto-600
N/A
_______________________________________________
4

Phyto-low
262.9 ± 107.3
Phyto-600
317.2 ± 129.6
_______________________________________________
5

Phyto-low
Before
202.0 ± 29.0**
After
340.0 ± 44.1
Phyto-600
Before
338.2 ± 38.7
After
313.6 ± 59.7
_______________________________________________
** Phyto-low Before value significantly lower than After
value; Before refers to serum measured prior to 1st Porsolt
test; After refers to serum measured after 2nd Porsolt test.
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Figures

Figure 1: Experiment 1 Intact Diet-Changed Female Body Weight Changes. Up arrow change in body weight prior to
equol injection was significantly different compared to down arrow, suggesting equol’s anti-obesity actions.
indicates
indicates time body weights were significantly different between treatment groups.
diet treatment start and finish date;
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Figure 2A: Experiment 1 Intact Diet-Changed Females 1st Porsolt Forced Swim Test
Body Weight (MEAN ± SEM). Test before diet change. * indicates that diet was
changed following run. There were no significant differences between treatment groups.

Figure 2B: Experiment 1 Intact Diet-Changed Females 1st Porsolt Forced Swim Test
Time Immobile (MEAN ± SEM). Test before diet change. * indicates that diet was
changed following run. There were no significant differences between treatment groups.
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Figure 2C: Experiment 1 Intact Diet-Changed Females 1st Porsolt Forced Swim Test
Total Distance Travelled (MEAN ± SEM). Test before diet change. * indicates that diet
was changed following run. There were no significant differences between treatment
groups.

Figure 2D: Experiment 1 Intact Diet-Changed Females 1st Porsolt Forced Swim Test
Overall Average Speed (MEAN ± SEM). Test before diet change. * indicates that diet
was changed following run. There were no significant differences between treatment
groups.
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Figure 3A: Experiment 1 Intact Diet-Changed Females 2nd Porsolt Forced Swim Test
Body Weight (MEAN ± SEM). 30 days after diet change.
Phyto-600 animals
weighed significantly less than Phyto-low animals.

Figure 3B: Experiment 1 Intact Diet-Changed Females 2nd Porsolt Forced Swim Test
Time Immobile (MEAN ± SEM). 30 days after diet change. There were no significant
differences between treatment groups.
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Figure 3C: Experiment 1 Intact Diet-Changed Females 2nd Porsolt Forced Swim Test
Total Distance Travelled (MEAN ± SEM). 30 days after diet change. There were no
significant differences between treatment groups.

Figure 3D: Experiment 1 Intact Diet-Changed Females 2nd Porsolt Forced Swim Test
Overall Average Speed (MEAN ± SEM). 30 days after diet change. There were no
significant differences between treatment groups.
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Figure 4A: Experiment 1 Intact Diet-Changed Females 3rd Porsolt Forced Swim Test
Body Weight (MEAN ± SEM). 80 days after diet treatment (diet switched) and after 7
days of equol injections in the Phyto-low animals.
Phyto-600 animals weighed
significantly less than Phyto-low animals.

Figure 4B: Experiment 1 Intact Diet-Changed Females 3rd Porsolt Forced Swim Test
Time Immobile (MEAN ± SEM). 80 days after diet treatment (diet switched) and after 7
days of equol injections in the Phyto-low animals. There were no significant differences
between treatment groups.
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Figure 4C: Experiment 1 Intact Diet-Changed Females 3rd Porsolt Forced Swim Test
Total Distance Travelled (MEAN ± SEM). 80 days after diet treatment (diet switched)
and after 7 days of equol injections in the Phyto-low animals. There were no significant
differences between treatment groups.

Figure 4D: Experiment 1 Intact Diet-Changed Females 3rd Porsolt Forced Swim Test
Overall Average Speed (MEAN ± SEM). 80 days after diet treatment (diet switched) and
after 7 days of equol injections in the Phyto-low animals. There were no significant
differences between treatment groups.
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Figure 5A: Experiment 1 Intact Diet-Changed Females Body Weight At the End of The
Experiment (MEAN ± SEM).
= Phyto-600 animals weighed significantly less than
Phyto-low animals.

Figure 5B: Experiment 1 Intact Diet-Changed Females White Adipose Tissue (MEAN ±
SEM).
= Phyto-600 animals significantly lower than Phyto-low animals.
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Figure 5C: Experiment 1 Intact Diet-Changed Females WAT/BW Ratio (MEAN ±
SEM). WAT = White adipose tissue deposition. BW = body weight.
= Phyto-600
animals significantly lower than Phyto-low animals.
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Figure 6: Experiment 2 Intact Lifelong Diet Female Body Weight Changes. Up arrow
change in body weight prior to equol injection was significantly different compared to
down arrow, suggesting equol’s anti-obesity actions.
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Figure 7A: Experiment 2 Intact Lifelong Diet Females 1st Porsolt Forced Swim Test
Body Weight (MEAN ± SEM). Animals age 115 days. There were no significant
differences between treatment groups.

Figure 7B: Experiment 2 Intact Lifelong Diet Females 1st Porsolt Forced Swim Test
Time Immobile (MEAN ± SEM). Animals age 115 days. There were no significant
differences between treatment groups.
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Figure 7C: Experiment 2 Intact Lifelong Diet Females 1st Porsolt Forced Swim Test
Total Distance Travelled (MEAN ± SEM). Animals age 115 days. There were no
significant differences between treatment groups.

Figure 7D: Experiment 2 Intact Lifelong Diet Females 1st Porsolt Forced Swim Test
Overall Average Speed (MEAN ± SEM). Animals age 115 days. There were no
significant differences between treatment groups.
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Figure 8A: Experiment 2 Intact Lifelong Diet Females 2nd Porsolt Forced Swim Test
Body Weight (MEAN ± SEM). Animals age 142 days and following 4 days of equol
injections in the Phyto-low animals. There were no significant differences between
treatment groups.

Figure 8B: Experiment 2 Intact Lifelong Diet Females 2nd Porsolt Forced Swim Test
Time Immobile (MEAN ± SEM). Animals age 142 days and following 4 days of equol
injections in the Phyto-low animals. There were no significant differences between
treatment groups.
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Figure 8C: Experiment 2 Intact Lifelong Diet Females 2nd Porsolt Forced Swim Test
Total Distance Travelled (MEAN ± SEM). Animals age 142 days and following 4 days
of equol injections in the Phyto-low animals. There were no significant differences
between treatment groups.

Figure 8D: Experiment 2 Intact Lifelong Diet Females 2nd Porsolt Forced Swim Test
Overall Average Speed (MEAN ± SEM). Animals age 142 days and following 4 days of
equol injections in the Phyto-low animals. There were no significant differences between
treatment groups.
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Figure 9A: Experiment 2 Intact Lifelong Diet Females Body Weight At the End of the
Experiment (MEAN ± SEM). There were no significant differences between treatment
groups.

Figure 9B: Experiment 2 Intact Lifelong Diet Females White Adipose Tissue (MEAN ±
SEM). There were no significant differences between treatment groups.
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Figure 9C: Experiment 2 Intact Lifelong Diet Females BW/WAT Ratio (MEAN ±
SEM). There were no significant differences between treatment groups.
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Figure 10: Experiment 3 Ovariectomized Diet-Changed Female Body Weight Changes.
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Figure 11A: Experiment 3 Ovariectomized Females Porsolt Forced Swim Test Body
Weight (MEAN ± SEM). There were no significant differences between treatment
groups.

Figure 11B: Experiment 3 Ovariectomized Females Porsolt Forced Swim Test Time
Immobile (MEAN ± SEM). There were no significant differences between treatment
groups.
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Figure 11C: Experiment 3 Ovariectomized Females Porsolt Forced Swim Test Total
Distance Travelled (MEAN ± SEM). There were no significant differences between
treatment groups.

Figure 11D: Experiment 3 Ovariectomized Females Porsolt Forced Swim Test Overall
Average Speed (MEAN ± SEM). There were no significant differences between
treatment groups.
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Figure 12A: Experiment 3 Ovariectomized Females Body Weight At the End of the
Experiment (MEAN ± SEM). There were no significant differences between treatment
groups.

Figure 12B: Experiment 3 Ovariectomized Females White Adipose Tissue (MEAN ±
Phyto-600 animals WAT significantly lower than Phyto-low animals.
SEM).
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Figure 12C: Experiment 3 Ovariectomized Females White Adipose Tissue to Body
Weight Ratio (MEAN ± SEM). There were no significant differences between treatment
groups.
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Figure 13: Experiment 4 Ovariectomized Lifelong Diet Female Body Weight Changes. Up arrow change in body weight prior to
indicates time body
equol injection was significantly different compared to down arrow, suggesting equol’s anti-obesity actions.
weights were significantly different between treatment groups.
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Figure 14A: Experiment 4 Ovariectomized Females 1st Porsolt Forced Swim Test Body
Phyto-600 animals weighed
Weight (MEAN ± SEM). Animals age 150 days.
significantly less than Phyto-low animals.

Figure 14B: Experiment 4 Ovariectomized Females 1st Porsolt Forced Swim Test Time
Immobile (MEAN ± SEM). Animals age 150 days. There were no significant differences
between treatment groups.
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Figure 14C: Experiment 4 Ovariectomized Females 1st Porsolt Forced Swim Test Total
Distance Travelled (MEAN ± SEM). Animals age 150 days. There were no significant
differences between treatment groups.

Figure 14D: Experiment 4 Ovariectomized Females 1st Porsolt Forced Swim Test
Overall Average Speed (MEAN ± SEM). Animals age 150 days. There were no
significant differences between treatment groups.
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Figure 15: Experiment 4 Ovariectomized Females 2nd Porsolt Forced Swim Test Body
Weight (MEAN ± SEM). Animals age 200 days and following 4 days of equol injections
in the Phyto-low females.
Phyto-600 animals weighed significantly less than Phytolow animals.
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Figure 16A: Experiment 4 Ovariectomized Females 3rd Porsolt Forced Swim Test
(MEAN ± SEM). Animals age 220 days and following 24 days of equol injections in the
Phyto-low females. There were no significant differences between treatment groups.

Figure 16B: Experiment 4 Ovariectomized Females 3rd Porsolt Forced Swim Test
(MEAN ± SEM). Animals age 220 days and following 24 days of equol injections in the
Phyto-low females. There were no significant differences between treatment groups.
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Figure 16C: Experiment 4 Ovariectomized Females 3rd Porsolt Forced Swim Test
(MEAN ± SEM). Animals age 220 days and following 24 days of equol injections in the
Phyto-low females. There were no significant differences between treatment groups.

Figure 16D: Experiment 4 Ovariectomized Females 3rd Porsolt Forced Swim Test
(MEAN ± SEM). Animals age 220 days and following 24 days of equol injections in the
Phyto-low females. There were no significant differences between treatment groups.
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Figure 17A: Experiment 4 Ovariectomized Females Body Weight At the End of the
Experiment (MEAN ± SEM). There were no significant differences between treatment
groups.

Figure 17B: Experiment 4 Ovariectomized Females White Adipose Tissue (MEAN ±
SEM). There were no significant differences between treatment groups.
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Figure 17C: Experiment 4 Ovariectomized Females White Adipose Tissue to Body
Weight Ratio (MEAN ± SEM). There were no significant differences between treatment
groups.
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Figure 18A: Experiment 5 Natural Ovarian Failure Females 1st Porsolt Forced Swim Test
Body Weight (MEAN ± SEM). Animals age 330 days.
Phyto-600 animals weighed
significantly less than Phyto-low animals.

Figure 18B: Experiment 5 Natural Ovarian Failure Females 1st Porsolt Forced Swim Test
Time Immobile (MEAN ± SEM). Animals age 330 days.
Phyto-600 animals spent
significantly less time immobile than Phyto-low animals.
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Figure 18C: Experiment 5 Natural Ovarian Failure Females 1st Porsolt Forced Swim Test
Phyto-low
Total Distance Travelled (MEAN ± SEM). Animals age 330 days.
animals swam a significantly shorter distance than Phyto-600 animals.

Figure 18D: Experiment 5 Natural Ovarian Failure Females 1st Porsolt Forced Swim Test
Phyto-low animals
Overall Average Speed (MEAN ± SEM). Animals age 330 days.
swam significantly slower than Phyto-600 animals.
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Figure 19A: Experiment 5 Natural Ovarian Failure Females 2nd Porsolt Forced Swim
Test Body Weight (MEAN ± SEM). Animals age 360 days and following 7 days of equol
injections in the Phyto-low females. There were no significant differences between
treatment groups.

Figure 19B: Experiment 5 Natural Ovarian Failure Females 2nd Porsolt Forced Swim
Test Time Immobile (MEAN ± SEM). Animals age 360 days and following 7 days of
equol injections in the Phyto-low females. There were no significant differences between
treatment groups.
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Figure 19C: Experiment 5 Natural Ovarian Failure Females 2nd Porsolt Forced Swim
Test Total Distance Travelled (MEAN ± SEM). Animals age 360 days and following 7
days of equol injections in the Phyto-low females. There were no significant differences
between treatment groups.

Figure 19D: Experiment 5 Natural Ovarian Failure Females 2nd Porsolt Forced Swim
Test Overall Average Speed (MEAN ± SEM). Animals age 360 days and following 7
days of equol injections in the Phyto-low females. There were no significant differences
between treatment groups.
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Figure 20A: Experiment 5 Natural Ovarian Failure Females At the End of the
Experiment Body Weight (MEAN ± SEM).

Figure 20B: Experiment 5 Natural Ovarian Failure Females White Adipose Tissue
(MEAN ± SEM).
Phyto-600 animals had significantly less white adipose tissue than
Phyto-low animals.
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Figure 20C: Experiment 5 Natural Ovarian Failure Females White Adipose Tissue to
Body Weight Ratio (MEAN ± SEM).
Phyto-600 animals had a significantly lower
white adipose tissue to body weight ratio than Phyto-low animals.
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Figure 21A: Experiment 1 Serum Isoflavone Levels (ng/ml ± 1.0).
were significantly lower than Phyto-600 values.

Phyto-low values
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Figure 21B: Experiment 2 Serum Isoflavone Levels (ng/ml ± 1.0).
were significantly lower than Phyto-600 values.

Phyto-low values
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Figure 21C: Experiment 3 Serum Isoflavone Levels (ng/ml ± 1.0).
were significantly lower than Phyto-600 values.

Phyto-low values
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Figure 21D: Experiment 4 Serum Isoflavone Levels (ng/ml ± 1.0).
Phyto-low values
Phyto-600 values were significantly
were significantly lower than Phyto-600 values.
lower than Phyto-low values.
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Phyto-low values
Figure 21E: Experiment 5 Serum Isoflavone Levels (ng/ml ± 1.0).
were significantly lower than Phyto-600 values. Before refers to serum drawn prior to 1st
Porsolt test, After refers to serum measured after 2nd Porsolt test.
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Figure 22: Experiment 5 Natural Ovarian Failure Serotonin Levels (ng/ml ± 1.0).
Phyto-low Before values were significantly lower than Phyto-low After values. Before
refers to serum drawn prior to 1st Porsolt test, After refers to serum measured after 2nd
Porsolt test.
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Figure 23: Experiment 5 Natural Ovarian Failure Females Summary Serotonin Values, Equol Values, Time Immobile and Body
Phyto-600 animals spent significantly less time immobile than Phyto-low animals.
Phyto-low After values were
Weight.
significantly lower than Phyto-low Before values.,
Phyto-low After values were significantly higher than Phyto-low Before
values.,
Phyto-low Before values were significantly lower than Phyto-low After values.,
Phyto-600 animals weighed
st
significantly less than Phyto-low animals, Before refers to serum drawn prior to 1 Porsolt test, After refers to serum measured after
2nd Porsolt test.
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